COMPARE · Data as of August 28, 2026
EFC vs NLY
Verdict: Side-by-side breakdown using the Bull Rankings model. EFC scored 65.0, NLY scored 70.0 — NLY leads.
Compare another set
Different reporting periods. NLY's fundamentals are as of June 2026, but EFC's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
EFC
Ellington Financial Inc.
77.5Fin
$13.57 · $1.8B
fundamentals as of
Strength gap
4.9
EFC leads
NLY
Annaly Capital Management, Inc.
72.6Fin
$23.04 · $17.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthNLY+87.3%
- Strongest balance sheetNLY7.38
Side by side · every name on one set of axes
Fundamentals, head-to-head
EFC
NLY
11.6%C+
Yield
13.0%C+
+8.6%B
Rev
+87.3%A
9.29D
D/E
7.38D
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
EFCEllington Financial Inc.
Why now
REIT - Mortgage · market cap $1.8b. 4% off the 52-week high of $14.12. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $14.86 (implying +9% upside).
Moat
Net margin 52% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
D/E 9.29 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Dividend payout 98% of earnings on a 11.6% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
NLYAnnaly Capital Management, Inc.
Why now
REIT - Mortgage · market cap $17.4b. 6% off the 52-week high of $24.52. Revenue growing +87% — in hypergrowth territory. 11 sell-side analysts publish a mean 1-yr target of $24.23 (implying +5% upside).
Moat
Net margin 91% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 7.38 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.